

# Fact Sheet


## UBS (Lux) Equity SICAV - All China (USD)

UBS Emerging Market Funds > Equities

### Fund description

- Actively managed equity fund based on an equity portfolio investing in selected Chinese companies.
- The manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
- Diversified across sectors offering broad coverage of the onshore and offshore Chinese equity market.

### Performance (share class P-acc USD, gross of sales charge)<sup>1</sup>



### Market exposure (%)

|                 | Fund |
|-----------------|------|
| China offshore  | 68.5 |
| China A onshore | 18.0 |
| Cash            | 13.6 |

### Sector exposure (%)

|                        | Fund  | Index | Deviation from Index |
|------------------------|-------|-------|----------------------|
| Financial Services     | 16.27 | 14.74 | 1.53                 |
| Consumer Discretionary | 16.14 | 25.15 | -9.01                |
| Communication Services | 15.70 | 12.72 | 2.98                 |
| Others / Cash          | 13.56 | 0.14  | 13.42                |
| Health Care            | 12.71 | 9.60  | 3.11                 |
| Consumer Staples       | 12.39 | 9.00  | 3.39                 |
| Real Estate            | 4.89  | 3.25  | 1.64                 |
| Information Technology | 3.28  | 9.07  | -5.79                |
| Industrials            | 2.60  | 8.22  | -5.62                |
| Materials              | 1.55  | 4.80  | -3.25                |
| Utility                | 0.91  | 1.91  | -1.00                |
| Energy                 | 0.00  | 1.40  | -1.40                |

### 10 largest equity positions (%)

|                           | Fund | Fund                             |      |
|---------------------------|------|----------------------------------|------|
| TENCENT HOLDINGS LTD      | 9.66 | CSPC PHARMACEUTICAL GROUP LT     | 3.68 |
| ALIBABA GROUP HOLDING LTD | 8.47 | HONG KONG EXCHANGES & CLEAR HKD1 | 3.47 |
| KWEICHOW MOUTAI CO LTD A  | 8.03 | PING AN BANK CO LTD A            | 3.05 |
| NETEASE INC-ADR           | 5.46 | CHINA MERCHANTS BANK CNY1        | 2.86 |
| PING AN INSURANCE H CNY1  | 4.07 | WULIANGYE YIBIN CO LTD A         | 2.78 |

# UBS (Lux) Equity SICAV - All China (USD)

|                          |  |
|--------------------------|--|
| Name of fund             | UBS (Lux) Equity SICAV - All China (USD) |
| Currency of fund         | USD                                      |
| Fund type                | Open-end                                 |
| Domicile                 | Luxembourg                               |
| Accounting year ends     | 31 May                                   |
| Total fund assets(USD m) | 4 581.49                                 |
| Ref Index                | MSCI China All-Share (net div. reinv.)   |
| Distribution             | Reinvestment                             |
| Management fee % p.a     | 1.72                                     |
| Total expense ratio p.a. | 2.24                                     |

## Fund statistics

|                | 3 years | 5 years |
|----------------|---------|---------|
| Beta           | 0.90    | n.a.    |
| Volatility*    |         |         |
| – Fund         | 18.54%  | n.a.    |
| – Ref Index    | 19.56%  | n.a.    |
| Sharpe ratio   | 0.71    | n.a.    |
| Risk free rate | 1.37%   | n.a.    |

\*Annualised standard deviation

## For questions about the Fund:

### UBS Fund Infoline: +65 6495 8000

Internet: [www.ubs.com/luxembourgfunds](http://www.ubs.com/luxembourgfunds)  
Contact your client advisor

## Portfolio management representatives

Bin Shi  
Morris Wu  
Denise Cheung

## General Fund Information as of (2021-06-30)

|           | NAV <sup>1</sup> | Annualized Distribution Yield (%) <sup>2</sup> | Latest Distribution     | Bloomberg  | ISIN code    |
|-----------|------------------|--|-------------------------|------------|--------------|
| P-acc USD | 139.39           | Distribution reinvested                        | Distribution reinvested | UBACNPA LX | LU1807302812 |
| P-acc HKD | 1408.77          | Distribution reinvested                        | Distribution reinvested | UBAACPA LX | LU1960683339 |
| P-acc SGD | 145.54           | Distribution reinvested                        | Distribution reinvested | UBACSGD LX | LU1993786604 |

<sup>1</sup>NAV and latest distribution in currency of share class

<sup>2</sup>Distribution yield is derived from simple arithmetic calculation where the dividend is divided by the NAV, and annualized thereafter. Note: The P-mdist share class makes monthly and gross of fee distributions while the P-dist share class makes annual and net of fee distributions.

## Cumulative Return<sup>1</sup>

| Share class                       | 2021 YTD <sup>2</sup> | 1 year | 3 year | Since Launch | Launch Date |
|-----------------------------------|-----------------------|--------|--------|--------------|-------------|
| P-acc USD (Gross of Sales Charge) | -4.37                 | 11.70  | 44.72  | 39.39        | 24.05.2018  |
| P-acc USD (Net of Sales Charge)   | -7.24                 | 8.35   | 40.37  | 35.21        | 24.05.2018  |
| Ref Index <sup>3</sup>            | 3.11                  | 32.22  | 46.94  | n.a.         |             |

## Annualized Return<sup>1</sup>

| Share class                       | 2021 YTD <sup>2</sup> | 1 year | 3 year | Since Launch | Launch Date |
|-----------------------------------|-----------------------|--------|--------|--------------|-------------|
| P-acc USD (Gross of Sales Charge) | -4.37                 | 11.70  | 13.11  | 11.29        | 24.05.2018  |
| P-acc USD (Net of Sales Charge)   | -7.24                 | 8.35   | 11.97  | 10.21        | 24.05.2018  |
| Ref Index <sup>3</sup>            | 3.11                  | 32.22  | 13.69  | n.a.         |             |

<sup>1</sup>Returns are shown net of total expense ratio and calculated on a single pricing basis. Net of sales charge returns are calculated based on a sales charge of 3%. Past performance is not necessarily indicative of future performance or results. Source for all data and charts (if not indicated otherwise): UBS Asset Management

<sup>2</sup>YTD: year-to-date (since beginning of the year)

<sup>3</sup>Reference Index in currency of share class (without costs)

## Risks

UBS Emerging Market Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate from that of its reference index. Investors should also be aware of the political and social challenges that emerging markets face. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

UBS (Lux) Equity SICAV (the "Fund"), a Luxembourg open-ended investment company, is the responsible person for the Fund's sub-fund, UBS (Lux) Equity SICAV - All China (USD), (the "Sub-Fund") recognised under Section 287 of the Securities and Futures Act of Singapore. UBS Asset Management (Singapore) Ltd (Company Registration No.: 199308367C) has been appointed as the Singapore representative ("UBS AM SG").

Investors should read the Singapore prospectus ("Prospectus") for further details before deciding to subscribe for or purchase units in the Sub-Fund, a copy of which can be downloaded from our website. The Prospectus can also be obtained free of charge from UBS AM SG, or from any of our authorized distributors as listed in our website. The price of the units in the Sub-Fund and the income accruing to those units, if any, may fall as well as rise. The Sub-Fund may use or invest in financial derivative instruments\* to the extent permitted under Luxembourg laws. Due to the investment policies and/or portfolio management techniques of the Sub-Fund, it may experience greater volatility in its net asset value\*. Investments in the Sub-Fund are not deposits in, obligations of, or guaranteed or insured by UBS AM SG, UBS AG, UBS Asset Management or any of their subsidiaries, associates or affiliates or distributors of the Sub-Fund and are subject to investment risks, including the possible loss of the principal amount investment. Past performance of the Sub-Fund, the management company and the portfolio manager and any past performance, prediction, projection, forecasts or information on the economic trends or securities market are not necessarily indicative of the future or likely performance of the Sub-Fund or the management company or the portfolio manager or a guarantee of future trends. Any extraordinary performance may be due to exceptional circumstances which may not be sustainable. No responsibility can be accepted by the management company or the portfolio manager to anyone for any action taken on the basis of the analysis. No representation or promise as to the performance of the funds or the return on your investment is made. Units of the Sub-Fund are not available to U.S. persons.

The information about the Sub-Fund provided in this document does not constitute an offer or solicitation to deal in units of the Sub-Fund or investment advice or recommendation. It is for informational purposes only. This document was prepared without regard to the specific investment objective(s), financial situation or the particular needs of any person. It is based on certain assumptions, information and conditions available as at the relevant date(s) and may be subject to change at any time without notice. Nothing in this document should be construed as advice or a recommendation to buy or sell units in the Sub-Fund. Investors may wish to seek independent advice from a financial adviser before making a commitment to invest in the Sub-Fund). In the event an investor chooses not to seek advice from a financial adviser, the investor should consider whether the Sub-Fund is suitable for him.

© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

\*Please refer to the Prospectus for more information on the risks associated with investments in financial derivative instruments and the Sub-Fund's volatility.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.